American Tungsten & Antimony Ltd
ATALFDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Oct 25, 2026
11wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ferric Carboxymaltose (FCM) | Phase 2 | Restless Legs Syndrome (RLS) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in American Tungsten & Antimony Ltd's drug pipeline?→
CatalystAlert tracks 1 drug candidate in American Tungsten & Antimony Ltd's (ATALF) pipeline across Phase 2. Its lead program is Ferric Carboxymaltose (FCM) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is American Tungsten & Antimony Ltd's next FDA catalyst?→
American Tungsten & Antimony Ltd's (ATALF) next tracked catalyst is a Conference expected October 25, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATALF biotech catalysts?→
Add ATALF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow American Tungsten & Antimony Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.